Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Why traders should remain wary despite Venice Token’s weekend relief rally

Why traders should remain wary despite Venice Token’s weekend relief rally

AMBCryptoAMBCrypto2026/10/12 18:03

Venice Token [VVV] rallied by 4.46% in the last 24 hours. The privacy-first AI platform token faced a 27% drawdown from Monday, 5th October, to Friday, 9th October.

Coming off the back of such a tough week, the recent VVV gains were commendable. In fact, according to CoinMarketCap, the last 24 hours’ trading volume was 128% higher than the previous day’s.

The Open Interest behind VVV was up 8.5%, and the Spot CVD has been in a steady move higher. The Spot and perpetuals demand could be an encouraging sight. However, funding rates dipped into negative territory before press time hours to signal a slightly overcrowded short trade.

@media only screen and (min-width: 0px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 50px; transition: min-height 0.3s ease; } } @media only screen and (min-width: 640px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 90px; } }
AD

Venice Token’s outlook for the rest of October

On the daily timeframe, the swing structure was bullish. The previous swing high was broken in September to re-establish the bullish structure. This was intact, even at the time of writing, despite the previous week’s correction.

A daily session close below $21.13 will shift the structure bearishly and be the first warning sign of a downtrend. The technical indicators were already warning of a downtrend though.

The A/D indicator continued to slump lower, making multi-month lows. The CMF was at -0.22 and has been in negative territory for a good chunk of the past six months. Together, the two volume indicators highlighted the steady selling pressure on Venice Token despite its bullish price structure.

The pullback towards $21.13 also forced the Awesome Oscillator below the zero line to confirm that bearish momentum was prevalent.

Can VVV bulls fight back against the selling?

The $25-support level from September was broken earlier this month and was retested as resistance in recent hours. This retest was followed by a bearish engulfing candle, signaling that there was potential for a deeper price slide.

At the time of writing, Bitcoin’s [BTC] price had slid below $83K, sparking short-term altcoin market fear. Sustained market-wide selling will shift the Venice Token’s structure bearishly.

Final Summary

  • Venice Token had a bullish price structure on the 1-day chart.
  • Structure was precariously perched as volume indicators warned of steady selling pressure.

 

News Image 0News Image 1News Image 2
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11